drugset
drugset / Trial / NCT02658175

The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome

NCT02658175 ↗

Phase 3 Completed 68 enrolled Akcea Therapeutics Ionis Pharmaceuticals · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

An open-label study of volanesorsen (ISIS 304801) administered subcutaneously to participants with FCS.

Timeline

Start
2015-12-23
Primary completion
2020-01-15
Completion
2020-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Volanesorsen Antisense oligonucleotide 300 mg Subcutaneous

Indications

familial lipoprotein lipase deficiency hypertriglyceridemia 1